ABSTRACT
The ADMA-like pre-eclampsia in pregnant rats was modeled by daily introduction of L-NAME in a dose of 25 mg/kg for 7 days. L-arginine (200 mg/kg) prevented the development of arterial hypertension and a decrease in placentary microcirculation and microalbuminuria. The possibility of using L-arginine for the prevention of competitive eNOS inhibition by ADMA is discussed.
Subject(s)
Arginine/administration & dosage , Endothelium/drug effects , Hypertension/prevention & control , Placenta/drug effects , Pre-Eclampsia/drug therapy , Albuminuria/prevention & control , Animals , Arginine/therapeutic use , Blood Pressure/drug effects , Endothelium/physiology , Female , Humans , Injections, Intraperitoneal , Microcirculation/drug effects , Microcirculation/physiology , NG-Nitroarginine Methyl Ester/administration & dosage , NG-Nitroarginine Methyl Ester/adverse effects , Nitric Oxide Synthase Type III/metabolism , Placenta/blood supply , Pre-Eclampsia/chemically induced , Pre-Eclampsia/metabolism , Pregnancy , RatsABSTRACT
Modeling of NO deficiency by administration of L-NAME to rats led to the development of arterial hypertension and endothelial dysfunction. Pronounced endothelium and cardioprotective effects of impaza under these experimental conditions manifested more markedly during combined administration of the preparation with standard hypotensive preparations enalapril and losartan.
Subject(s)
Antibodies/therapeutic use , Enalapril/therapeutic use , Hypertension/drug therapy , Losartan/therapeutic use , Nitric Oxide/deficiency , Animals , Hypertension/chemically induced , Male , NG-Nitroarginine Methyl Ester/pharmacology , Rats , Rats, WistarABSTRACT
Experimental NO deficiency induced by L-NAME injection led to the development of arterial hypertension, endothelial dysfunction, and cardiomyocyte hypertrophy and reduced blood content of nitrates and nitrites. Impaza, NO donors, activators of NO-synthase, antioxidants, and antihypertensive preparations produced endothelium-protective effect of different degree.
Subject(s)
Antibodies/therapeutic use , Endothelium, Vascular/drug effects , Nitric Oxide/deficiency , Animals , Antihypertensive Agents/therapeutic use , Antioxidants/therapeutic use , Hypertension/chemically induced , Hypertension/drug therapy , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nitrates/metabolism , Nitric Oxide Donors/therapeutic use , Nitrites/metabolism , Rats , Rats, Wistar , Resveratrol , Stilbenes/therapeutic useABSTRACT
In tests on a group of 250 rats, we studied (i) the level of microcirculation in the muscles of a healthy limb in the norm and (ii) the dynamics of microcirculation for 6 h after treatment with pentoxifylline in a dose of 60 mg/kg dose and L-arginine in a dose of 30 and 200 mg/kg. The chronic ischemia was modeled by excision of basic femoral artery. There was no significant difference in pentoxyfilline-treated animals in comparison to the control. In the group treated with L-arginine in a dose of 30 mg/kg, a significant increase in microcirculation was observed on the 28-th day of experiment. In the group treated with L-arginine in a dose of 200 mg/kg, there was an increase of microcirculation in all terms of the experiment in comparison to the control. The results of laser doppler flow measurements are correlated with the results of morphological investigation.
Subject(s)
Arginine/therapeutic use , Hindlimb/blood supply , Ischemia/drug therapy , Muscle, Skeletal/blood supply , Pentoxifylline/therapeutic use , Vasodilator Agents/therapeutic use , Animals , Female , Ischemia/physiopathology , Laser-Doppler Flowmetry , Microcirculation , Nitric Oxide Synthase/antagonists & inhibitors , Rats , Rats, Wistar , Regional Blood FlowABSTRACT
In laboratory animals with endothelial dysfunction (nitric oxide deficiency) modeled by the introduction of NO-synthase inhibitor L-NAME, the activation of endothelioprotective effects of enalapril, lozartan, amlodipine, indapamide and nebivolol is revealed for their introduction in combination with L-arginine. This result was confirmed by the behavior of a generalizing parameter, the coefficient of endothelial dysfunction (CED) calculated using the results of tests on endothelium-dependent and -independent vasodilation.
Subject(s)
Arginine/pharmacology , Endothelium, Vascular/drug effects , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase Type III/metabolism , Nitric Oxide/metabolism , Vasodilation/drug effects , Animals , Antihypertensive Agents/pharmacology , Benzopyrans/pharmacology , Enalapril/pharmacology , Endothelium, Vascular/metabolism , Ethanolamines/pharmacology , Indapamide/pharmacology , Losartan/pharmacology , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nebivolol , Nitric Oxide/deficiency , Nitric Oxide Synthase Type III/antagonists & inhibitors , Rats , Rats, Wistar , Vasodilator Agents/pharmacologyABSTRACT
We studied the effects of antioxidants resveratrol and pQ510 on physiological parameters and the state of endothelial NO-synthase as a marker of the regulatory function of the endothelium in the aorta of rats with modeled arterial hypertension. The antioxidants promoted recovery of stable NO metabolites in rat serum and maintained expression of endothelial NO-synthase at a normal level. These effects were confirmed by correction of blood pressure and endothelium-dependent vascular dilation assessed by endothelial dysfunction coefficient.
